New trials to see if HIV virus can be ‘flushed out’: expert
- India's future cannot exist without the future of Kashmir: Rajnath Singh
- Will appoint nodal officer to help Kashmiri youth across the country: Rajnath Singh in Srinagar
- Dec 16 Delhi gangrape case: Convict attempts suicide inside Tihar Jail, rushed to hospital
- Earthquake in Italy kills 247, toll may rise as rescuers continue hunt for survivors
- Rahul Gandhi twisting statement, must show generosity, apologise: RSS
New clinical trials have been launched in the US and Europe to test whether HIV virus can be "flushed out" through a new approach of using anti-retrovirals and immune modulating agents, revealed Prof. Christine Katlama, Head of the AIDS Clinical Research Unit, Department of Infectious Diseases, Pitie-Salpetriere, Paris.
Katlama, who is in Pune to participate in the first annual meeting of the HIV Medicine Association, was impressed by the quality of research in India and hopes to invite Indian doctors to participate in a clinical research course in June in Europe this year.
The HIV Medicine Association's two-day meet begins on March 26 and will focus on educating physicians on aspects of HIV treatment, said Dr Sanjay Pujari, Director and Chief Consultant, Institute of Infectious Diseases.
Katlama told The Indian Express that despite controlling the virus in the US and Europe, many new infections are reported. "Can we eradicate the virus instead of just sustaining treatment...Can we lower levels enough to ensure a functional cure that can enable HIV positive people to safely stop antiretroviral therapy," said Katlama adding that the new trial launched in November last hoped to focus on a more potent strategy.
"Antiretrovirals would be combined with immune modulating agents to 'flush out' the latent cell reservoir by triggering silent integrated proviral DNA to start producing new virus. This will then be susceptible to the potent antiretroviral drug combination," says Katlama, adding that 30 people have been enrolled in the clinical trial being conducted by biopharmaceutical company Cytheris. Participants will intensify their current suppressive regimen by adding the 2 newest antiretroviral drug classes, along with interleukin 7 (IL-7) to activate resting CD4 T-cells, she explained.
Apart from Katlama , a host of experts will participate in the meeting, Pujari said.
- Sedition law cannot be used against honest views, expressed peacefully
- India’s dependence on China for medicine ingredients is a matter of concern
- Before Balochistan, India has supported some human rights causes and ignored others
- Olympics brought many smiles — and a little bit of rancour
- Harish Gupta case involves questions about the very nature of governmental decision-making
- Tension between the executive and judiciary could play out in creative, or destructive, ways